A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02C | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02C

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Melanoma
Age: Between 18 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:

1) Has histologically or cytologically confirmed melanoma. 2) Has clinically detectable and resectable Stage IIIB or IIIC or IIID melanoma amenable to surgery. 3) Has provided a baseline tumor biopsy.

You may not be eligible for this study if the following are true:

1) Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 7 days before the first dose of study intervention. 2) Has a known additional malignancy that is progressing or requires active treatment within the past 2 years. 3) Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.